Introduction
CML, Comorbidity
CML
The development of The phase 4 BYOND study was designed to provide further information on the efficacy and safety of bosutinib in patients with CP CML who were resistant/intolerant to prior TKIs [In patients with CML, previous studies have reported an association between higher Charlson Comorbidity Index (CCI) score and reduced overall survival (OS) [